Proscia has introduced the Fifth Generation of its Concentriq platform, marking the most significant architectural overhaul of the digital pathology software in five years. The update brings domain-specific vision, language, and multimodal AI models directly into the platform's core, serving both diagnostic laboratories and biopharmaceutical scientists across the drug discovery and development lifecycle.
The announcement comes as the broader digital pathology market accelerates. The market is valued at approximately $2 billion in 2026 and projected to surpass $3.2 billion by 2031, growing at a compound annual growth rate of nearly 10%, driven by rising cancer incidence and increasing use of AI in pathology interpretation. Within that market, the AI-in-pathology segment is expanding more sharply: it is projected to reach $347 million by 2030, up from $107 million in 2025, at a CAGR of 26.5%, with pharmaceutical and biopharmaceutical companies representing the fastest-growing end-user segment.
What changed in the fifth generation architecture
Earlier versions of Concentriq established Proscia as a leading enterprise digital pathology platform. The fifth generation introduces a new underlying architecture designed to unify images, metadata, and the full context surrounding a case or study, from slide-level morphology and patient history through to laboratory-specific protocols and translational data. The aim is to give both human experts and AI models the same complete picture before any analysis or recommendation is made.
The platform incorporates frontier vision models for tissue image analysis, large language models for natural-language interaction with data, and multimodal models that connect image findings with clinical context. Critically, Proscia says outputs are designed to be transparent, reproducible, and interpretable, supporting expert verification rather than replacing it.
"AI is advancing rapidly," said Coleman Stavish, CTO of Proscia. "We took a first-principles approach, working backwards from how pathologists and scientists operate. Years of learning from our customers has helped us understand where complexity slows them down and where judgment gets crowded out by process. Fifth Generation is designed to reduce that burden so experts can focus on the decisions that matter most."
The timing reflects a well-documented pressure point. According to the Royal College of Pathologists' 2025 Workforce Census, 54% of pathologists report not having sufficient time each day to complete their daily workload, with half citing excessive workload as a factor negatively affecting their wellbeing at work. AI-assisted case review is one of the mechanisms digital pathology vendors are deploying to address that gap, though the degree to which it translates to meaningful time savings in real-world lab conditions depends heavily on implementation quality.
How the platform serves diagnostic laboratories
For anatomic pathology labs, Concentriq Fifth Generation focuses on three areas: accelerating case review, automating laboratory operations, and enabling business growth through specialty testing.
On the case review side, the platform combines an intelligent viewer with built-in image analysis, allowing regions of interest to be refined and results to update in real time. Skin slides orient automatically to preserve the pathologist's spatial orientation. The platform assembles reportable findings within the same pass, reducing the need to toggle between systems.
For operations teams, AI-assisted workload balancing, stain panel recommendations, and automated storage tiering are among the features Proscia highlights. The company states, as a vendor-stated figure, that automated storage tiering can reduce long-term storage costs by more than half while preserving governed access for re-review, AI validation, and biopharma collaborations.
Key capabilities for diagnostic lab teams include:
- Intelligent navigation for faster tissue review, with automatic slide orientation
- Integrated image analysis with real-time region-of-interest refinement and supporting evidence
- Automated workload balancing and stain panel recommendations
- Purpose-built worklists and dashboards with multi-site, multi-scanner visibility
- Automated storage tiering with secure, governed data access
- Digital macro dissection and native AI tumor detection for molecular workflows
"As one of the first laboratories to go digital, we've seen firsthand how technology reshapes pathology, and Concentriq has enabled that journey," said Dr. Derek Welch, President and Chief Medical Officer of PathGroup. "Fifth Generation applies AI in an entirely new way, removing the invisible labor that surrounds case review so pathologists can spend more time on the decisions that only they can make."
Advanced Lab Management Certificate
The Advanced Lab Management certificate is more than training—it’s a professional advantage.
Gain critical skills and IACET-approved CEUs that make a measurable difference.
Biomarker discovery and clinical development for biopharma teams
The fifth generation's capabilities for life sciences users center on three phases of the drug development pipeline: early biomarker discovery, clinical trial execution, and the translation of validated diagnostics into routine clinical use.
For discovery, scientists can search across tissue, clinical, and translational data using plain-language queries. AI agents surface relevant evidence, propose analysis pipelines that scientists can edit and version, and help identify and assess biomarker candidates. The architecture is designed to carry findings forward so teams build on prior work rather than restart from scratch.
In clinical development, the platform predicts biomarker expression during pre-screening, helping sponsors identify eligible patients and reach enrollment targets faster. The system supports multi-site global trials with consistent patient evaluation criteria and reproducible results.
| Use case | Fifth generation capability |
|---|---|
| Biomarker discovery | Plain-language queries across tissue, clinical, and translational data; AI-proposed analysis pipelines |
| Pre-screening | Algorithmic prediction of biomarker expression to identify trial-eligible patients |
| Trial execution | Multi-site global support with consistent criteria and reproducible outputs |
| Companion diagnostic development | Assay building and validation with access to multimodal real-world data |
| Clinical adoption | Distribution of validated diagnostics across academic, reference, and health system labs |
"We use Concentriq to run anatomic pathology testing for drug development across multiple laboratories on three continents," said Dr. John Cochran, Vice President and Chief Medical Officer at IQVIA Laboratories. "Proscia has a bold vision for what pathology software can be. Fifth Generation applies that same thinking to AI, elevating pathologists and scientists and growing pathology's role in precision medicine."
Interested in lab design?
This dual positioning, serving both diagnostic labs and pharmaceutical R&D, is increasingly central to Proscia's market strategy. The platform functions as a network connecting labs managing patient cases with biopharma companies seeking access to real-world data, companion diagnostic collaborations, and clinical trial partnerships. AI algorithms assist in early cancer detection and biomarker quantification, and AI-enabled tools automate numerous routine tasks such as cell counting and tissue segmentation, allowing pathologists to focus on complex cases.
What lab managers considering digital pathology upgrades should know
Proscia holds the 2026 Best in KLAS designation for digital pathology, reflecting customer-reported performance across primary diagnosis, ease of use, and implementation support. That standing matters in a field where platform selection is becoming an increasingly consequential decision. Adoption in the US remains limited, with estimates suggesting only 10 to 15 percent of organizations have implemented digital pathology at any meaningful scale, and early insights indicate that organizations are hitting an adoption wall that has little to do with software performance, with system complexity and the human interface emerging as key limiting factors.
For lab managers weighing whether the fifth generation represents a meaningful upgrade, the relevant questions are practical ones: how the new AI features integrate with existing laboratory information systems, what the transition pathway looks like for labs already on Concentriq, and how the platform's agentic capabilities perform in real-world diagnostic workflows rather than controlled demonstrations. Lab Manager's coverage of how labs are navigating the digital pathology implementation gap and productivity gains from AI in digital pathology workflows offers useful context for teams at different stages of that journey.
The fifth generation is available now to current customers through Proscia's early access program. Initial deployments begin this month with select laboratories and biopharmaceutical companies, with broader availability expected later in 2026. Organizations not currently on the platform can request priority access directly from Proscia.
A live product walkthrough and demonstration webinar is scheduled for July 28, 2026 at 12 PM ET.
References
Royal College of Pathologists. Workforce Census 2025: Morale and Wellbeing of the Pathology Workforce. August 2025. Available at: https://www.rcpath.org/discover-pathology/news/workforce-census-2025-morale-and-wellbeing-of-the-pathology-workforce.html
MarketsandMarkets. AI in Pathology Market: Growth, Size, Share, and Trends. 2025. Available at: https://www.marketsandmarkets.com/Market-Reports/ai-in-pathology-market-86647266.html
Mordor Intelligence. Digital Pathology Market Growing at 9.9% CAGR to 2031 as AI Adoption Accelerates. January 2026. Available at: https://www.prnewswire.com/news-releases/digital-pathology-market-growing-at-9-9-cagr-to-2031-as-ai-adoption-accelerates-says-a-2026-mordor-intelligence-report-302663208.html
